Literature DB >> 31427449

Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.

Milton Maciel1,2,3, David Bauer4, Robin L Baudier4, Jacob Bitoun4, John D Clements4, Steven T Poole1, Mark A Smith5, Robert W Kaminski5, Stephen J Savarino3, Elizabeth B Norton6.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) is a major cause of infectious diarrhea in children, travelers, and deployed military personnel. As such, development of a vaccine would be advantageous for public health. One strategy is to use subunits of colonization factors combined with antigen/adjuvant toxoids as an ETEC vaccine. Here, we investigated the intradermal (i.d.) or sublingual (s.l.) delivery of CFA/I fimbrial antigens, including CfaEB and a CfaE-heat-labile toxin B subunit (LTB) chimera admixed with double mutant heat-labile toxin (LT) LT-R192G/L211A (dmLT). In addition, we compared dmLT with other LT proteins to better understand the generation of adjuvanted fimbrial and toxoid immunity as well as the influence on any local skin reactogenicity. We demonstrate that immunization with dmLT admixed with CfaEB induces robust serum and fecal antibody responses to CFA/I fimbriae and LT but that i.d. formulations are not optimal for s.l. delivery. Improved s.l. vaccination outcomes were observed when higher doses of dmLT (1 to 5 μg) were admixed with CfaEB or, even better, when a CfaE-LTB chimera antigen was used instead. Serum anti-CFA/I total antibodies, detected by enzyme-linked immunosorbent assay, were the best predictor of functional antibodies, based on the inhibition of red blood cell agglutination by ETEC. Immunization with other LT proteins or formulations with altered B-subunit binding during i.d. immunization (e.g., by addition of 5% lactose, LTA1, or LT-G33D) minimally altered the development of antibody responses and cytokine recall responses but reduced skin reactogenicity at the injection site. These results reveal how formulations and delivery parameters shape the adaptive immune responses to a toxoid and fimbria-derived subunit vaccine against ETEC.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CFA/I; ETEC; LTA1; dmLT; intradermal; sublingual; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31427449      PMCID: PMC6803349          DOI: 10.1128/IAI.00460-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

Review 1.  Intradermal fractional dose inactivated polio vaccine: a review of the literature.

Authors:  Katherine S Nelson; Julia M Janssen; Stephanie B Troy; Yvonne Maldonado
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

2.  Intradermal delivery for vaccine dose sparing: overview of current issues.

Authors:  Darin Zehrung; Courtney Jarrahian; Amy Wales
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

3.  Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.

Authors:  Stephen J Savarino; Robin McKenzie; David R Tribble; Chad K Porter; Aisling O'Dowd; Joyce A Cantrell; Stephanie A Sincock; Steven T Poole; Barbara DeNearing; Colleen M Woods; Hye Kim; Shannon L Grahek; Carl Brinkley; Joseph H Crabb; A Louis Bourgeois
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine.

Authors:  Brenda L Coleman; Allison J McGeer; Scott A Halperin; Joanne M Langley; Yassein Shamout; Anna Taddio; Vibhuti Shah; Shelly A McNeil
Journal:  Vaccine       Date:  2012-08-16       Impact factor: 3.641

5.  The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.

Authors:  Elizabeth B Norton; David L Bauer; William C Weldon; M Steven Oberste; Louise B Lawson; John D Clements
Journal:  Vaccine       Date:  2015-03-09       Impact factor: 3.641

6.  Structure of CFA/I fimbriae from enterotoxigenic Escherichia coli.

Authors:  Yong-Fu Li; Steven Poole; Kazuya Nishio; Ken Jang; Fatima Rasulova; Annette McVeigh; Stephen J Savarino; Di Xia; Esther Bullitt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-10       Impact factor: 11.205

7.  Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates.

Authors:  Stephanie A Sincock; Eric R Hall; Colleen M Woods; Aisling O'Dowd; Steven T Poole; Annette L McVeigh; Gladys Nunez; Nereyda Espinoza; Milagros Miller; Stephen J Savarino
Journal:  Vaccine       Date:  2015-11-18       Impact factor: 3.641

8.  Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

9.  Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.

Authors:  J Holmgren; L Bourgeois; N Carlin; J Clements; B Gustafsson; A Lundgren; E Nygren; J Tobias; R Walker; A-M Svennerholm
Journal:  Vaccine       Date:  2013-03-27       Impact factor: 3.641

10.  Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells.

Authors:  Lisa T Read; Rachel W Hahn; Carli C Thompson; David L Bauer; Elizabeth B Norton; John D Clements
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

View more
  10 in total

1.  Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling.

Authors:  Naoki Iwanaga; Kong Chen; Haoran Yang; Shiping Lu; Joseph P Hoffmann; Alanna Wanek; Janet E McCombs; Kejing Song; Javier Rangel-Moreno; Elizabeth B Norton; Jay K Kolls
Journal:  Sci Immunol       Date:  2021-09-10

2.  Preclinical optimization of an enterotoxigenic Escherichia coli adjuvanted subunit vaccine using response surface design of experiments.

Authors:  David Poncet; Catherine Hessler; Hong Liang; Sylviane Gautheron; Michelle Sergent; Nicholas D Rintala; Emilie Seydoux; Po-Wei D Huang; David Argilla; Sophie Ruiz; Jon Heinrichs; Milton Maciel; Mark T Orr
Journal:  NPJ Vaccines       Date:  2020-09-11       Impact factor: 7.344

3.  Evaluation of the Immunogenicity and Protective Efficacy of an Enterotoxigenic Escherichia coli CFA/I Adhesin-Heat-Labile Toxin Chimera.

Authors:  Aisling O'Dowd; Milton Maciel; Steven T Poole; Michael G Jobling; Julianne E Rollenhagen; Colleen M Woods; Stephanie A Sincock; Annette L McVeigh; Michael J Gregory; Ryan C Maves; Michael G Prouty; Randall K Holmes; Stephen J Savarino
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

4.  Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.

Authors:  Addison E Stone; Sarah E Scheuermann; Colin N Haile; Gregory D Cuny; Marcela Lopez Velasquez; Joshua P Linhuber; Anantha L Duddupudi; Jennifer R Vigliaturo; Marco Pravetoni; Therese A Kosten; Thomas R Kosten; Elizabeth B Norton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

Review 5.  Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.

Authors:  Ibrahim Khalil; Richard Walker; Chad K Porter; Farzana Muhib; Roma Chilengi; Alejandro Cravioto; Richard Guerrant; Ann-Mari Svennerholm; Firdausi Qadri; Shahida Baqar; Margaret Kosek; Gagandeep Kang; Claudio Lanata; George Armah; Thomas Wierzba; Mateusz Hasso-Agopsowicz; Birgitte Giersing; A Louis Bourgeois
Journal:  Vaccine       Date:  2021-05-06       Impact factor: 3.641

6.  Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.

Authors:  Milton Maciel; Mark Smith; Steven T Poole; Renee M Laird; Julianne E Rollenhagen; Robert W Kaminski; Heather Wenzel; A Louis Bourgeois; Stephen J Savarino
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

7.  LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms.

Authors:  Eduardo Valli; Robin L Baudier; Amanda J Harriett; Elizabeth B Norton
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

8.  Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.

Authors:  Tida Lee; Ramiro L Gutiérrez; Milton Maciel; Steven Poole; Kayla J Testa; Stefanie Trop; Christopher Duplessis; Alison Lane; Mark S Riddle; Melinda Hamer; Ashley Alcala; Michael Prouty; Nicole Maier; Rahsan Erdem; A Louis Bourgeois; Chad K Porter
Journal:  Vaccine       Date:  2021-08-18       Impact factor: 3.641

9.  Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.

Authors:  Jessica W Crothers; Elizabeth Ross Colgate; Kelly J Cowan; Dorothy M Dickson; MaryClaire Walsh; Marya Carmolli; Peter F Wright; Elizabeth B Norton; Beth D Kirkpatrick
Journal:  Vaccine       Date:  2022-03-30       Impact factor: 4.169

10.  U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.

Authors:  Lorena M Coria; Franco L Martinez; Laura A Bruno; Karina A Pasquevich; Juliana Cassataro
Journal:  Vaccine       Date:  2020-06-11       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.